Literature DB >> 19951017

Effect of apolipoprotein E genotype on the outcome after anterior cervical decompression and fusion in patients with cervical spondylotic myelopathy.

Matthias Setzer1, Frank D Vrionis, Elvis J Hermann, Volker Seifert, Gerhard Marquardt.   

Abstract

OBJECT: The authors examined a possible association between apolipoprotein E (APOE) gene polymorphism and the outcome after anterior microsurgical decompression in patients with cervical spondylotic myelopathy (CSM).
METHODS: The authors conducted a prospective study of 60 consecutive patients (40 men, 20 women) with CSM who underwent anterior microsurgical decompression. The patients ranged in age from 26 to 86 years (mean 61.5 +/- 14.6 years). Neurological deficits were classified according to the modified Japanese Orthopaedic Association Scale. Mean follow-up was 18.8 +/- 4.6 months and APOE genotyping was carried out by isolation of DNA from venous blood samples. The APOE genotypes were determined by polymerase chain reaction followed by restriction enzyme digestion and polyacrylamide gel electrophoresis of digested fragments. Categorical variables were analyzed with the chi-square test, continuous data with the Mann-Whitney U-test, and for multiple groups with the Kruskal-Wallis H-test. A backward stepwise binary logistic regression analysis was performed to determine the effect of APOE in a multivariate model.
RESULTS: Of the 60 patients with CSM, 35 (58.3%) improved and 25 (41.7%) did not improve or suffered deterioration (no-improvement group). In the improvement group 5 patients (8.3%) possessed the epsilon4 allele compared with 16 patients (26.7%) in the no-improvement group (p = 0.002, OR 3.3, 95% CI 1.7-6.1). In a multivariate model, the occurrence of the epsilon4 allele was a significant independent predictor for no improvement after anterior decompression and fusion (p = 0.004, OR 8.6, 95% CI 5.1-20.6).
CONCLUSIONS: The results of this study show that APOE gene polymorphism influences the short-term outcome of CSM patients after surgical decompressive and stabilizing therapy in the way that the presence of the APOE epsilon4 allele is an independent predictor for a no improvement. The presence of APOE may explain in part the different responses to operative therapies in patients with cervical myelopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951017     DOI: 10.3171/2009.7.SPINE08667

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  9 in total

1.  Proteomic analysis of cerebrospinal fluid in canine cervical spondylomyelopathy.

Authors:  Paula Martin-Vaquero; Ronaldo C da Costa; Matthew J Allen; Sarah A Moore; Jeremy K Keirsey; Kari B Green
Journal:  Spine (Phila Pa 1976)       Date:  2015-05-01       Impact factor: 3.468

2.  HIF-1α polymorphism in the susceptibility of cervical spondylotic myelopathy and its outcome after anterior cervical corpectomy and fusion treatment.

Authors:  Zhan-Chao Wang; Xu-Wei Hou; Jiang Shao; Yong-Jing Ji; Lulu Li; Qiang Zhou; Si-Ming Yu; Yu-Lun Mao; Hao-Jie Zhang; Ping-Chao Zhang; Hua Lu
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

Review 3.  Genetics Underlying an Individualized Approach to Adult Spinal Disorders.

Authors:  Corey T Walker; Phillip A Bonney; Nikolay L Martirosyan; Nicholas Theodore
Journal:  Front Surg       Date:  2016-11-22

Review 4.  Ossification of the Posterior Longitudinal Ligament in Cervical Spine: Prevalence, Management, and Prognosis.

Authors:  Jau-Ching Wu; Yu-Chun Chen; Wen-Cheng Huang
Journal:  Neurospine       Date:  2018-03-28

Review 5.  Change in Functional Impairment, Disability, and Quality of Life Following Operative Treatment for Degenerative Cervical Myelopathy: A Systematic Review and Meta-Analysis.

Authors:  Michael G Fehlings; Lindsay A Tetreault; Shekar Kurpad; Darrel S Brodke; Jefferson R Wilson; Justin S Smith; Paul M Arnold; Erika D Brodt; Joseph R Dettori
Journal:  Global Spine J       Date:  2017-09-05

6.  A New Framework for Investigating the Biological Basis of Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 5]: Mechanical Stress, Vulnerability and Time.

Authors:  Benjamin M Davies; Oliver Mowforth; Aref-Ali Gharooni; Lindsay Tetreault; Aria Nouri; Rana S Dhillon; Josef Bednarik; Allan R Martin; Adam Young; Hitoshi Takahashi; Timothy F Boerger; Virginia Fj Newcombe; Carl Moritz Zipser; Patrick Freund; Paul Aarne Koljonen; Ricardo Rodrigues-Pinto; Vafa Rahimi-Movaghar; Jefferson R Wilson; Shekar N Kurpad; Michael G Fehlings; Brian K Kwon; James S Harrop; James D Guest; Armin Curt; Mark R N Kotter
Journal:  Global Spine J       Date:  2022-02

7.  A Clinical Practice Guideline for the Management of Patients With Degenerative Cervical Myelopathy: Recommendations for Patients With Mild, Moderate, and Severe Disease and Nonmyelopathic Patients With Evidence of Cord Compression.

Authors:  Michael G Fehlings; Lindsay A Tetreault; K Daniel Riew; James W Middleton; Bizhan Aarabi; Paul M Arnold; Darrel S Brodke; Anthony S Burns; Simon Carette; Robert Chen; Kazuhiro Chiba; Joseph R Dettori; Julio C Furlan; James S Harrop; Langston T Holly; Sukhvinder Kalsi-Ryan; Mark Kotter; Brian K Kwon; Allan R Martin; James Milligan; Hiroaki Nakashima; Narihito Nagoshi; John Rhee; Anoushka Singh; Andrea C Skelly; Sumeet Sodhi; Jefferson R Wilson; Albert Yee; Jeffrey C Wang
Journal:  Global Spine J       Date:  2017-09-05

Review 8.  Genetics of Degenerative Cervical Myelopathy: A Systematic Review and Meta-Analysis of Candidate Gene Studies.

Authors:  Daniel H Pope; Benjamin M Davies; Oliver D Mowforth; A Ramsay Bowden; Mark R N Kotter
Journal:  J Clin Med       Date:  2020-01-20       Impact factor: 4.241

9.  The influence of ApoE4 on the clinical outcomes and pathophysiology of degenerative cervical myelopathy.

Authors:  Alexa Desimone; James Hong; Sydney T Brockie; Wenru Yu; Alex M Laliberte; Michael G Fehlings
Journal:  JCI Insight       Date:  2021-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.